Stockreport

Global Autologous Stem Cell & Non-Stem Cell Therapies Market: $5.5B in 2024 to $22.2B by 2029, CAGR 32.3% | MarketsandMarkets™ [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF revenue expected to rise from $5.5 billion in 2024 to $22.2 billion by 2029, at a CAGR of 32.3%. Key drivers include increasing regulatory approvals for autologous CAR T [Read more]